Aiki na Pfizer A Kashi na Uku na Alurar COVID-19 Wanda 'Ƙarfi' ke Ƙarfafa Kariya

Wadatacce

• Bita don

Tun da farko wannan bazara, ya ji kamar cutar ta COVID-19 ta koma gefe. Cibiyoyin Kula da Cututtuka da Cututtuka sun gaya wa mutanen da ke da cikakken alurar riga kafi a watan Mayu cewa ba sa buƙatar sanya abin rufe fuska a yawancin saitunan, kuma adadin COVID-19 a cikin Amurka ya ragu na ɗan lokaci. Amma sai, bambancin Delta (B.1.617.2) da gaske ya fara juyar da mummunan kan sa.

Bambancin Delta yana da alhakin kusan kashi 82 na sabbin shari'o'in COVID-19 a cikin Amurka har zuwa 17 ga Yuli, a cewar bayanai daga CDC. Hakanan yana da alaƙa da haɗarin haɗarin asibiti na kashi 85 cikin ɗari fiye da sauran igiya, kuma yana da kashi 60 cikin ɗari fiye da bambancin Alpha (B.1.17), nau'in da ya fi rinjaye a baya, a cewar binciken Yuni 2021. (Mai alaƙa: Me yasa Sabuwar Delta COVID COVID ta bambanta sosai?)

Nazarin kwanan nan daga Ingila da Scotland sun nuna cewa maganin Pfizer ba shi da tasiri wajen karewa daga bambance-bambancen Delta kamar yadda yake ga Alpha, a cewar CDC. Yanzu, wannan ba yana nufin allurar rigakafin ba za ta iya taimaka muku ku kawar da cututtukan da ke nuna alamun cutar ba - yana nufin cewa ba ta da tasiri wajen yin hakan idan aka kwatanta da ikon yin yaƙi da Alpha. Amma wasu labarai masu yuwuwa: A ranar Laraba, Pfizer ya ba da sanarwar cewa kashi na uku na allurar COVID-19 na iya haɓaka kariya daga bambancin Delta, fiye da hakan daga allurai biyu na yanzu. (Mai Alaƙa: Ta yaya Alurar COVID-19 ke Inganci)

Bayanai da aka buga akan layi daga Pfizer yana ba da shawarar cewa kashi na uku na allurar na iya samar da matakan antibody sama da sau biyar a kan bambancin Delta a cikin mutane tsakanin 18 zuwa 55 idan aka kwatanta da hakan daga daidaitattun allurai biyu. Kuma, bisa ga binciken da kamfanin ya yi, mai ƙarfafawa ya fi tasiri a cikin mutane masu shekaru 65 zuwa 85, yana ƙara matakan rigakafin kusan sau 11 a tsakanin wannan ƙungiyar. Duk abin da ake faɗi, saitin bayanan ya kasance ƙanana - mutane 23 ne kawai ke da hannu - kuma har yanzu ba a sake nazarin binciken ba ko kuma buga su a cikin mujallar likita tukuna.

Mikael ya ce "Muna ci gaba da yin imani da alama akwai yuwuwar ana iya buƙatar ƙaramin kashi na uku a cikin watanni shida zuwa 12 bayan cikakken allurar rigakafin don kula da mafi girman matakan kariya, kuma ana ci gaba da nazari don kimanta aminci da rigakafin rigakafi na kashi na uku," in ji Mikael Dolsten, MD, Ph.D., babban jami'in kimiyya kuma shugaban Bincike na Duniya, Ci gaba, da Medicalfor Pfizer, a cikin wata sanarwa Laraba. Dolsten ya ci gaba da karawa da cewa, "Wadannan bayanan farko suna da kwarin gwiwa sosai yayin da Delta ke ci gaba da yaduwa."

A bayyane yake, kariyar da daidaitaccen allurar Pfizer na kashi biyu na iya farawa "ya ragu" watanni shida bayan allurar, bisa ga gabatarwar babbar masana'antar harhada magunguna a ranar Laraba. Don haka, yuwuwar kashi na uku na iya zama mai taimako musamman, a sauƙaƙe, ɗaukaka kariyar mutane daga COVID-19 gaba ɗaya. Yana da mahimmanci a lura, duk da haka, cewa matakan rigakafin ƙwayoyin cuta - kodayake wani muhimmin al'amari na rigakafi - ba shine kawai ma'auni don auna ikon mutum na yaƙar ƙwayar cuta ba, a cewar Jaridar New York Times. A takaice, ana buƙatar ƙarin lokaci da bincike don fahimtar da gaske ko kashi na uku na Pfizer shine, kuskure, duk abin da ya fashe ya zama.

Baya ga Pfizer, sauran masu yin alluran rigakafin suma sun goyi bayan ra'ayin harbin kara kuzari. Derrick Rossi wanda ya kirkiro Moderna ya fada Labaran CTV a farkon watan Yuli cewa za a buƙaci harbi na yau da kullun na rigakafin COVID-19 "kusan" don kiyaye rigakafi daga cutar. Rossie har ya kai ga cewa, "Yana iya zama ba abin mamaki bane cewa muna buƙatar harbi mai ƙaruwa kowace shekara." (Mai dangantaka: Kuna iya Buƙatar Sashi na Uku na Allurar COVID-19)

Shugaban Kamfanin Johnson & Johnson Alex Gorsky shi ma ya yi tsalle a kan masu karawa a cikin jirgin a lokacin Jaridar Wall Street Journal'Taron Lafiya na Tech a farkon watan Yuni, yana mai cewa za a buƙaci ƙarin allurai (s) don allurar rigakafin kamfaninsa - aƙalla har sai an sami rigakafin garken garken (aka lokacin da yawancin jama'a ba sa kamuwa da cutar). Ya kara da cewa "Muna iya kallon wannan alamar tare da cutar mura, mai yiwuwa a cikin shekaru masu zuwa," in ji shi.

Amma a farkon watan Yuli, CDC da Hukumar Abinci da Magunguna sun fitar da sanarwar hadin gwiwa da ke cewa "Amurkawan da aka yi wa cikakken allurar rigakafin ba sa bukatar karin harbi a wannan lokacin" kuma "FDA, CDC, da NIH [Cibiyoyin Kiwon Lafiya na Kasa" ] sun tsunduma cikin tushen kimiyya, tsauraran tsari don yin la'akari ko ko lokacin da mai haɓaka zai iya zama dole."

"Muna ci gaba da yin nazarin duk wani sabon bayanai yayin da yake samuwa kuma za mu sanar da jama'a," in ji sanarwar "Mun shirya don ƙarin allurai idan kuma lokacin da kimiyya ta nuna cewa ana buƙatar su."

A zahiri, a ranar Laraba Dr. Dolsten ya ce Pfizer yana cikin "tattaunawa mai gudana" tare da hukumomin da ke da tsari a Amurka game da yuwuwar kashi na uku na rigakafin rigakafin yanzu. Idan hukumomi sun yanke shawarar cewa ya zama dole, Pfizer yana shirin ƙaddamar da aikace-aikacen izinin amfani da gaggawa a cikin watan Agusta, a cewar Dr. Dolstein. Ainihin, ana iya samun harbin COVID-19 a cikin shekara mai zuwa.

Bayanai a cikin wannan labarin daidai ne har zuwa lokacin da ake bugawa. Yayin da sabuntawa game da coronavirus COVID-19 ke ci gaba da haɓaka, yana yiwuwa wasu bayanai da shawarwari a cikin wannan labarin sun canza tun farkon bugawa. Muna ƙarfafa ku da ku bincika akai-akai tare da albarkatu kamar CDC, WHO, da sashin kula da lafiyar jama'a na gida don ƙarin sabbin bayanai da shawarwari.

Bita don